Brought to you by 
Syndax pays up to $374.5mm to license CSF-1R antibody from UCB
06 Feb 2017
Executive Summary
UCB Group granted Syndax Pharmaceuticals Inc. exclusive global rights to develop, manufacture, and sell its anti-colony stimulating factor-1R (CSF-1R) monoclonal antibody UCB6352, which Syndax will refer to as SNDX6352.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Syndax pays up to $374.5mm to license CSF-1R antibody from UCB
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice